Zynex (NASDAQ:ZYXI) Releases Q2 Earnings Guidance

Zynex (NASDAQ:ZYXI) issued an update on its second quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.08 for the period, compared to the consensus EPS estimate of $0.07. The company issued revenue guidance of $52 million, compared to the consensus revenue estimate of $53.13 million. Zynex also updated its FY 2024 guidance to 0.500- EPS.

Zynex Trading Down 4.2 %

NASDAQ ZYXI traded down $0.48 during trading hours on Tuesday, reaching $10.97. The company’s stock had a trading volume of 156,777 shares, compared to its average volume of 233,515. The firm has a fifty day simple moving average of $12.38 and a 200-day simple moving average of $10.81. The stock has a market cap of $352.90 million, a P/E ratio of 42.41 and a beta of 0.48. Zynex has a 52 week low of $6.88 and a 52 week high of $14.75. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.74 and a quick ratio of 4.03.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, February 29th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.13). Zynex had a return on equity of 16.82% and a net margin of 5.28%. The company had revenue of $47.28 million for the quarter, compared to the consensus estimate of $54.53 million. During the same period in the prior year, the business earned $0.20 earnings per share. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. Equities analysts forecast that Zynex will post 0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZYXI has been the topic of a number of recent analyst reports. Royal Bank of Canada boosted their price target on shares of Zynex from $13.00 to $15.00 and gave the stock an outperform rating in a research report on Friday, March 1st. HC Wainwright increased their price target on Zynex from $20.00 to $21.00 and gave the stock a buy rating in a report on Friday, March 1st.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.